

Rec'd PCT/PTO 18 OCT 2004 H2

Europäisches  
PatentamtEuropean  
Patent OfficeOffice européen  
des brevets10/511627  
REC'D 11 JUN 2003

WIPO

PCT

**Bescheinigung****Certificate****Attestation**

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

**Patentanmeldung Nr. Patent application No. Demande de brevet n°**

02010948.4

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk



Anmeldung Nr:  
Application no.: 02010948.4  
Demande no:

Anmelde tag:  
Date of filing: 16.05.02  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

DeveloGen Aktiengesellschaft für  
entwicklungsbiologische Forschung  
Rudolf-Wissell-Strasse 28  
37079 Göttingen  
ALLEMAGNE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se referer à la description.)

CG14440, Gpdh, Synaptojanin-like homologous proteins involved in the regulation  
of energy homeostasis

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

A61K38/00

Am Anmelde tag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignés lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

16. Mai 2002

# WEICKMANN & WEICKMANN

Patentanwälte  
European Patent Attorneys · European Trademark Attorneys

EPO - Munich  
80  
16. Mai 2002

Unser Zeichen:  
28138P EP/WWcl

DIPLO-ING. H. WEICKMANN (bis 31.1.01)  
DIPLO-ING. F. A. WEICKMANN  
DIPLO-CHEM. B. HUBER  
DR-ING. H. LISKA  
DIPLO-PHYS. DR. J. PRECHTEL  
DIPLO-CHEM. DR. B. BÖHM  
DIPLO-CHEM. DR. W. WEISS  
DIPLO-PHYS. DR. J. TIESMEYER  
DIPLO-PHYS. DR. M. HERZOG  
DIPLO-PHYS. B. RUTTENSPERGER  
DIPLO-PHYS. DR-ING. V. JORDAN  
DIPLO-CHEM. DR. M. DEY  
DIPLO-FORSTW. DR. J. LACHNIT

Anmelder:  
DeveloGen Aktiengesellschaft für  
entwicklungsbiologische Forschung  
Rudolf-Wissell-Straße 28  
  
37079 Göttingen  
DEUTSCHLAND

---

CG14440, Gpdh, Synaptojanin-like homologous proteins involved in the regulation of energy homeostasis

---

EPO - Munich  
80  
16. Mai 2002

- 1 -

**CG14440, Gpdh, Synaptjanin-like homologous proteins involved in the regulation of energy homeostasis**

5 . **Description**

This invention relates to the use of nucleic acid sequences encoding CG14440, Gpdh, or Synaptjanin-like homologous proteins, and the polypeptides encoded thereby and to the use thereof in the diagnosis, 10 study, prevention, and treatment of diseases and disorders related to body-weight regulation, for example, but not limited to, metabolic diseases such as obesity as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancer, e.g. 15 cancers of the reproductive organs, and sleep apnea.

Obesity is one of the most prevalent metabolic disorders in the world. It is still a poorly understood human disease that becomes more and more relevant for western society. Obesity is defined as an excess of body fat, 20 frequently resulting in a significant impairment of health. Besides severe risks of illness such as diabetes, hypertension and heart disease, individuals suffering from obesity are often isolated socially. Human obesity is strongly influenced by environmental and genetic factors, whereby the environmental influence is often a hurdle for the identification of (human) 25 obesity genes. Obesity is influenced by genetic, metabolic, biochemical, psychological, and behavioral factors. As such, it is a complex disorder that must be addressed on several fronts to achieve lasting positive clinical outcome. Obese individuals are prone to ailments including: diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, 30 dyslipidemia, osteoarthritis, gallstones, cancers of the reproductive organs, and sleep apnea.

Obesity is not to be considered as a single disorder but a heterogeneous group of conditions with (potential) multiple causes. Obesity is also characterized by elevated fasting plasma insulin and an exaggerated insulin response to oral glucose intake (Koltermann, J. Clin. Invest 65, 1980, 5 1272-1284) and a clear involvement of obesity in type 2 diabetes mellitus can be confirmed (Kopelman, Nature 404, 2000, 635-643).

Even if several candidate genes have been described which are supposed to influence the homeostatic system(s) that regulate body mass/weight, 10 like leptin, VCPI, VCPL or the peroxisome proliferator-activated receptor-gamma co-activator, the distinct molecular mechanisms and/or molecules influencing obesity or body weight/body mass regulations are not known.

15 Therefore, the technical problem underlying the present invention was to provide for means and methods for modulating (pathological) metabolic conditions influencing body-weight regulation and/or energy homeostatic circuits. The solution to said technical problem is achieved by providing the embodiments characterized in the claims.

20 Accordingly, the present invention relates to genes with novel functions in body-weight regulation, energy homeostasis, metabolism, and obesity. The present invention discloses specific genes involved in the regulation of body-weight, energy homeostasis, metabolism, and obesity, and thus in 25 disorders related thereto such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancer, e.g. cancers of the reproductive organs, and sleep apnea. In particular, the present invention describes the human CG14440, Glycerol-3-phosphate dehydrogenase (referred to as Gpdh or G3PDH), or Synaptojanin-like homologous genes as 30 being involved in those conditions mentioned above.

The term 'GenBank Accession number' relates to NCBI GenBank database entries (Benson et al, Nucleic Acids Res. 28, 2000, 15-18).

The Drosophila gene with GadFly Accession Number CG14440 encodes for  
5 a protein which is most homologous to the human hypothetical protein LOC55565 (GenBank Accession Number NP\_060000.1 for the protein, NM\_017530 for the cDNA). No functional data are available for these proteins in the prior art.

10

Glycerol-3-phosphate dehydrogenase (G3PDH) catalyzes the following reaction: Dihydroxyacetone phosphate, NADH, and H<sup>+</sup> react to L-glycerol-3-phosphate and NAD<sup>+</sup>. G3PDH activity has been demonstrated in a wide variety of species belonging to animal as well as plant kingdoms  
15 (Lin E.C., 1977, Annu Rev Biochem. 46:765-795). Drosophila Gpdh encodes a glycerol-3-phosphate dehydrogenase (NAD<sup>+</sup>) involved in glycerophosphate shuttle in the cytoplasm. NAD-dependent glycerol-3-phosphate dehydrogenase (EC 1.1.1.8) is a cytoplasmic protein, active as a homodimer (Von Kalm L. et al., 1989, Proc. Natl. Acad. Sci.  
20 U.S.A. 86:5020-5024) each monomer containing an N-terminal NAD binding site (Otto J. et al., 1980, Eur. J. Biochem. 109: 325-330). It is necessary for the transfer of the H<sup>+</sup> of the NADH - generated in the glycolysis - from the cytoplasm into the mitochondria, where it is used in the respiratory chain. In insects, it acts in conjunction with a mitochondrial alpha-glycerophosphate oxidase in the alpha-glycerophosphate cycle, which is essential for the production of energy used in insect flight. G3PDH catalyzes the reversible reduction of dihydroxyacetone phosphate (with 2 H<sup>+</sup>) to glycerol-3-phosphate, which can diffuse in the mitochondria, where reoxidation regenerates the products and leads to FADH2 (2 ATP).

25

Comparisons of physicochemical characteristics, tissue distribution and coenzyme requirement point to a separate genetic determination and low

level of evolutionary relatedness between mitochondrial glycerol-3-phosphate dehydrogenase (GPDM) and its cytosolic counterpart (GPDS) (Shaw M.A. et al., 1982, Ann Hum Genet 46(Pt 1):11-23).

5 A marked reduction in G3PDH activity was observed in chronic plaques of multiple sclerosis (Hirsch H.E. et al, 1980, J. Neurochem. 34(3):760-762). Insulin exposure stimulates an increase in G3PDH activity in human lymphocytes that correlates to an increase in G3PDH mRNA. The insulin stimulation of G3PDH activity is decreased in obese individuals. Treatment  
10 of those patients by a very low calorie diet restores insulin stimulation of G3PDH activity. Thus, insulin stimulation of G3PDH activity is dependent upon the metabolic state of the subject from whom the cells are obtained (Tu et al., 1995, Biochem Biophys Res Commun 207(1):183-190). However, although a stimulation of G3PDH by insulin was described in the  
15 prior art, it has not been described in the prior art that G3PDH is directly involved in the regulation of energy homeostasis and thus involved in the storage of triglycerides.

20 Synaptic vesicles are recycled with remarkable speed and precision in nerve terminals. A major recycling pathway involves clathrin-mediated endocytosis at endocytic zones located around sites of release. Different 'accessory' proteins linked to this pathway have been shown to alter the shape and composition of lipid membranes, to modify membrane-coat protein interactions, and to influence actin polymerization. These include  
25 the GTPase dynamin, the lysophosphatidic acid acyl transferase endophilin, and the phosphoinositide phosphatase synaptojanin (Brodin L. et al., 2000, Curr Opin Neurobiol 10(3):312-320). Studies on the endocytosis of synaptic vesicles have shown the essential roles of endophilin and synaptojanin in vesicle formation (see, Ringstad N. et al., 1999, Neuron 30 24(1):143-154). The recessive suppressor of secretory defect in yeast Golgi and yeast actin function belongs to this family (Luo W. and Chang A., 1997, J Cell Biol 138(4):731-746). This protein may be involved in the

coordination of the activities of the secretory pathway and the actin cytoskeleton. Human synaptjanin, which may be localised on coated endocytic intermediates in nerve terminals also belongs to this family (Haffner C. et al., 1997, FEBS Lett 419(2-3):175-180). Studies on the 5 endocytosis of synaptic vesicles have shown the essential roles of endophilin and synaptjanin in vesicle formation (see, Ringstad N. et al., 1999, Neuron 24(1):143-154).

So far, it has not been described that CG14440, Gpdh, or Synaptjanin-like 10 and homologous proteins are involved in the regulation of energy homeostasis and body-weight regulation and related disorders, and thus, no functions in metabolic diseases and other diseases as listed above have been discussed. In this invention we demonstrate that the correct gene dose of CG14440, Gpdh, or Synaptjanin-like is essential for maintenance 15 of energy homeostasis. A genetic screen was used to identify that mutation of CG14440, Gpdh, or Synaptjanin-like homologous genes cause obesity, reflected by a significant change of triglyceride content, the major energy storage substance.

Before the present proteins, nucleotide sequences, and methods are 20 described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is 25 not intended to limit the scope of the present invention that will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those 30 described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated herein by

reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies that are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure.

The present invention discloses that CG14440, Gpdh, or Synaptojanin-like homologous proteins are regulating the energy homeostasis and fat metabolism especially the metabolism and storage of triglycerides, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides of the invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders, for example, but not limited to, metabolic diseases such as obesity as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancer, e.g. cancers of the reproductive organs, and sleep apnea.

CG14440, Gpdh, or Synaptojanin-like homologous proteins and nucleic acid molecules coding therefore are obtainable from insect or vertebrate species, e.g. mammals or birds. Particularly preferred are homologous nucleic acids, particularly nucleic acids encoding the human hypothetical protein LOC55565, human soluble glycerol-3-phosphate dehydrogenase 1, or human KIAA0966 protein.

The invention particularly relates to a nucleic acid molecule encoding a polypeptide contributing to regulating the energy homeostasis and the metabolism of triglycerides, wherein said nucleic acid molecule comprises  
(a) the nucleotide sequence of (i) CG14440 (GadFly Accession Number), or encoding the human hypothetical protein LOC55565,

- (ii) Gpdh (Glycerol 3 phosphate dehydrogenase, **GadFly** Accession Number CG9042), or encoding the human soluble glycerol-3-phosphate dehydrogenase 1, or (iii) CG7956 (GadFly Accession Number), or encoding human KIAA0966 protein, and/or a sequence complementary thereto,
- 5 (b) a nucleotide sequence which hybridizes at 50°C in a solution containing 1 x SSC and 0.1% SDS to a sequence of (a),
- (c) a sequence corresponding to the sequences of (a) or (b) within the degeneration of the genetic code,
- 10 (d) a sequence which encodes a polypeptide which is at least 85%, preferably at least 90%, more preferably at least 95%, more preferably at least 98% and up to 99.6% identical to the amino acid sequences of CG14440, Gpdh, or Synaptjanin-like protein, preferably of the human hypothetical protein LOC55565, human soluble glycerol-3-phosphate dehydrogenase 1, or human KIAA0966 protein,
- 15 (e) a sequence which differs from the nucleic acid molecule of (a) to (d) by mutation and wherein said mutation causes an alteration, deletion, duplication and/or premature stop in the encoded polypeptide or
- 20 (f) a partial sequence of any of the nucleotide sequences of (a) to (e) having a length of at least 15 bases, preferably at least 20 bases, more preferably at least 25 bases and most preferably at least 50 bases.

25 The present invention relates to genes with novel functions in body-weight regulation, energy homeostasis, metabolism, and obesity. The invention is based on the finding that CG14440, Gpdh, or Synaptjanin-like homologous proteins (herein referred to as CG14440, Gpdh, or Synaptjanin-like) and the polynucleotides encoding these, are involved in the regulation of triglyceride storage and therefore energy homeostasis. To find genes with novel functions in energy homeostasis, metabolism, and

obesity, a functional genetic screen was performed with the model organism *Drosophila melanogaster* (Meigen). One resource for screening was a *Drosophila melanogaster* stock collection of EP-lines. The P-vector of this collection has Gal4-UAS-binding sites fused to a basal promoter that can transcribe adjacent genomic *Drosophila* sequences upon binding of Gal4 to UAS-sites. This enables the EP-line collection for overexpression of endogenous flanking gene sequences. In addition, without activation of the UAS-sites, integration of the EP-element into the gene is likely to cause a reduction of gene activity, and allows determining its function by evaluating the loss-of-function phenotype.

Triglycerides are the most efficient storage for energy in cells, and obese patients mainly show a significant increase in the content of triglycerides. In order to isolate genes with a function in energy homeostasis, several thousand EP-lines were tested for their triglyceride content after a prolonged feeding period (see Examples for more detail). Lines with significantly changed triglyceride content were selected as positive candidates for further analysis. The increase or decrease of triglyceride content due to the loss of a gene function suggests gene activities in energy homeostasis in a dose dependent manner that controls the amount of energy stored as triglycerides.

In this invention, the content of triglycerides of a pool of flies with the same genotype after feeding for six days was analyzed using a triglyceride assay. Male flies homozygous for the integration of vectors for *Drosophila* lines PX10162.1, HD-EP(2)21956, or HD-EP(3)31805 were analyzed in an assay measuring the triglyceride contents of these flies, illustrated in more detail in the EXAMPLES section. The results of the triglyceride content analysis are shown in FIGURES 1, 4 and 7, respectively.

30

Genomic DNA sequences were isolated that are localized to the EP vector (herein PX10162.1, HD-EP(2)21956, or HD-EP(3)31805) integration. Using

those isolated genomic sequences public databases like Berkeley Drosophila Genome Project (GadFly) were screened thereby identifying the integration site of the vectors, and the corresponding genes, described in more detail in the EXAMPLES section. The molecular organization of the genes is shown in FIGURES 2, 5 and 8, respectively.

The present invention further describes polypeptides comprising the amino acid sequences of CG14440, Gpdh, or Synaptjanin-like and homologous proteins. Based upon homology, the proteins of the invention and each homologous protein or peptide may share at least some activity. No functional data described the regulation of body weight control and related metabolic diseases are available in the prior art for the genes of the invention.

The invention also encompasses polynucleotides that encode CG14440, Gpdh, or Synaptjanin-like and homologous proteins. Accordingly, any nucleic acid sequence, which encodes the amino acid sequences of CG14440, Gpdh, or Synaptjanin-like and homologous proteins, can be used to generate recombinant molecules that express CG14440, Gpdh, or Synaptjanin-like and homologous proteins. In a particular embodiment, the invention encompasses a nucleic acid encoding CG14440 (GadFly Accession Number), the human hypothetical protein LOC55565, Gpdh (Glycerol 3 phosphate dehydrogenase, GadFly Accession Number CG9042), the human soluble glycerol-3-phosphate dehydrogenase 1, CG7956 (GadFly Accession Number), or the human KIAA0966 protein. It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding the proteins, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance

with the standard triplet genetic code as applied to the nucleotide sequences of naturally occurring CG14440, Gpdh, or Synaptjanin-like and homologous proteins, and all such variations are to be considered as being specifically disclosed. Although nucleotide sequences, which encode the proteins, and their variants are preferably capable of hybridizing to the nucleotide sequences of the naturally occurring proteins under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding the proteins or their derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding the proteins and their derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequences. The invention also encompasses production of DNA sequences or portions thereof, which encode the proteins and their derivatives, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents that are well known in the art at the time of the filing of this application. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding the protein or any portion thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed nucleotide sequences, and in particular, those of the polynucleotide encoding CG14440 (GadFly Accession Number), the human hypothetical protein LOC55565, Gpdh (Glycerol 3 phosphate dehydrogenase, GadFly Accession Number CG9042), the human soluble glycerol-3-phosphate dehydrogenase 1, CG7956 (GadFly Accession Number), or the human KIAA0966 protein,

under various conditions of stringency. Hybridization conditions are based on the melting temperature ( $T_m$ ) of the nucleic acid binding complex or probe, as taught in Wahl, G. M. and S. L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A. R. (1987; Methods Enzymol. 152:507-511), and may be used at a defined stringency. Preferably, hybridization under stringent conditions means that after washing for 1 h with 1 x SSC and 0.1% SDS at 50°C, preferably at 55°C, more preferably at 62°C and most preferably at 68°C, particularly for 1 h in 0.2 x SSC and 0.1% SDS at 50°C, preferably at 55°C, more preferably at 62°C and most preferably at 68°C, a positive hybridization signal is observed. Altered nucleic acid sequences encoding the proteins which are encompassed by the invention include deletions, insertions or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent protein.

The encoded proteins may also contain deletions, insertions or substitutions of amino acid residues, which produce a silent change and result in functionally equivalent proteins. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of the protein is retained.

Also included within the scope of the present invention are alleles of the genes encoding CG 14440, Gpdh, or Synaptojanin-like and homologous proteins. As used herein, an 'allele' or 'allelic sequence' is an alternative form of the gene, which may result from at least one mutation in the nucleic acid sequence. Alleles may result in altered mRNAs or polypeptides whose structures or function may or may not be altered. Any given gene may have none, one or many allelic forms. Common mutational changes, which give rise to alleles, are generally ascribed to natural deletions, additions or substitutions of nucleotides. Each of these types of changes may occur alone or in combination with the others, one or more times in a

given sequence. Methods for DNA sequencing which are well known and generally available in the art may be used to practice any embodiments of the invention.

5      The nucleic acid sequences encoding CG1 4440, Gpdh, or Synaptjanin-like and homologous proteins may be extended utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed, 'restriction-site' PCR, uses  
10     universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). Inverse PCR may also be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186). The primers may be designed using OLIGO 4.06 primer analysis software  
15     (National Biosciences Inc., Plymouth, Minn.) or another appropriate program, to 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72°C. The method uses several restriction enzymes to generate suitable fragments. The fragment is then circularized by intramolecular  
20     ligation and used as a PCR template.

Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (PCR Methods Applic. 1:111-119). In this method, multiple restriction enzyme digestions and ligations also are used to place an engineered double-stranded sequence into an unknown portion of the DNA molecule before performing PCR.

30     Another method which may be used to retrieve unknown sequences is that of Parker, J. D. et al. (1991; Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER

libraries to walk in genomic DNA (Clontech, Palo Alto, Calif.). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

- 5 When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences, which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not
- 10 yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into the 5' and 3' non-transcribed regulatory regions. Capillary electrophoresis systems, which are commercially available, may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers
- 15 for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity may be converted to electrical signal using appropriate software (e.g. GENOTYPER and SEQUENCE NAVIGATOR, Perkin Elmer) and the entire
- 20 process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA, which might be present in limited amounts in a particular sample.
- 25 In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode CG14440, Gpdh, or Synaptosomal-like and homologous proteins or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct expression of the proteins in appropriate host cells. Due to the inherent degeneracy of the
- 30 genetic code, other DNA sequences, which encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express the proteins. As will be

understood by those of skill in the art, it may be advantageous to produce protein-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression  
5 or to produce a recombinant RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence. The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter protein-encoding sequences for a variety of reasons,  
10 including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, site-directed mutagenesis may be used to insert  
15 new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants or introduce mutations, and so forth.

In another embodiment of the invention, natural, modified or recombinant nucleic acid sequences encoding CG14440, Gpdh, or Synaptjanin-like and homologous proteins may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen libraries, e.g. peptide libraries or low-molecular weight compound libraries for inhibitors of CG14440, Gpdh, or Synaptjanin-like and homologous protein activities, it may be useful to encode chimeric proteins that can be recognized by a commercially available antibodies. A fusion protein may also be engineered to contain a cleavage site located between the desired protein-encoding sequence and the heterologous protein sequence so that the desired protein may be cleaved and purified away from the heterologous moiety. In another embodiment, sequences encoding the protein may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M. H. et al. (1980) Nucl. Acids Res. Symp. Ser. 7:215-223, Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 7:225-232).

Alternatively, the proteins themselves may be produced using chemical methods to synthesize the amino acid sequence of the protein or a portion thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J. Y. et al. (1995) *Science* 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A peptide synthesizer (Perkin Elmer). The newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) *Proteins, Structures and Molecular Principles*, WH Freeman and Co., New York, N.Y.). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; Creighton, supra). Additionally, the amino acid sequences of the proteins or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins or any part thereof, to produce a variant polypeptide.

In order to express a biologically active protein, the nucleotide sequences encoding the proteins or functional equivalents, may be inserted into appropriate expression vectors, i.e., a vector, which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods, which are well known to those skilled in the art, may be used to construct expression vectors containing sequences encoding the proteins and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described in Sambrook, J. et al. (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, Plainview, N.Y., and Ausubel, F. M. et al. (1989) *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, N.Y.

A variety of expression vector/host systems may be utilized to contain and express sequences encoding the proteins. These include, but are not

limited to, micro-organisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems 5 transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or PBR322 plasmids); or animal cell systems. The "control elements" or "regulatory sequences" are those non-translated regions of the vector-enhancers, promoters, 5' and 3' untranslated regions which interact with host cellular proteins to carry out transcription and 10 translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, 15 inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or PSPORT1 plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters and enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO; and storage protein genes) or from plant 20 viruses (e.g., viral promoters and leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequences encoding the protein, vectors based on SV40 or EBV may be used with an appropriate selectable 25 marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for the protein. For example, when large quantities of protein are needed for the induction of antibodies, vectors, 30 which direct high level expression of fusion proteins that are readily purified, may be used. Such vectors include, but are not limited to, the multifunctional E. coli cloning and expression vectors such as the

BLUESCRIPT phagemid (Stratagene), in which the sequences encoding the protein may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of  $\beta$ -galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503-5509); and the like. PGE<sub>X</sub> vectors (Promega, Madison, Wis.) may also be used to express foreign polypeptides as fusion proteins with Glutathione S-Transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will. In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al., (supra) and Grant et al. (1987) Methods Enzymol. 153:516-544.

In cases where plant expression vectors are used, the expression of sequences encoding the proteins may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L. E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, N.Y.; pp. 191-196).

An insect system may also be used to express the proteins. For example, in one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. The sequences encoding the protein may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and place under control of the polyhedrin promoter. Successful insertions of the protein will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, *S. frugiperda* cells of *Trichoplusia* larvae in which CG14440, Gpdh, or Synaptjanin-like and homologous proteins may be expressed (Engelhard, E. K. et al. (1994) Proc. Nat. Acad. Sci. 91:3224-3227).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding the protein may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain viable viruses which are capable of expressing the protein in infected host cells (Logan, J. and Shenk, T. (1984) Proc. Natl. Acad. Sci. 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding the protein. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding the protein, its initiation codons, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be

provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion 5 of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the 10 expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing 15 which cleaves a 'prepro' form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, HEK293, and WI38, which have specific cellular machinery and characteristic mechanisms for such post-translational activities, may be chosen to ensure the correct modification and processing of the foreign protein..

For long-term, high-yield production of recombinant proteins, stable 20 expression is preferred. For example, cell lines which stably express CG14440, Gpdh, or Synaptojanin-like and homologous proteins may be generated by transformation using expression vectors which may contain 25 viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells, which successfully express 30 the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980) Cell 22:817-23) genes,  
5 which can be employed in tk- or aprt-cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418  
10 (Colbere-Garapin, F. et al (1981) J. Mol. Biol. 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described, for example, trpB, which allows cells to utilise indole  
15 in place of tryptophan or hisD, which allows cells to utilise histidol in place of histidine (Hartman, S. C. and R. C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins,  $\beta$ -glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of  
20 transient or stable protein expression attributable to a specific vector system (Rhodes, C. A. et al. (1995) Methods Mol. Biol. 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need  
25 to be confirmed. For example, if the sequences encoding the protein of interest are inserted within a marker gene sequence, recombinant cells containing sequences encoding the protein can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with sequences encoding the protein under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well. Alternatively, host cells, which contain and express the nucleic acid  
30

sequences encoding the protein may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques that include membrane, solution or chip based technologies for the detection and/or quantification of nucleic acid or protein.

The presence of polynucleotide sequences encoding CG14440, Gpdh, or Synaptjanin-like and homologous proteins can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or portions or fragments of polynucleotides encoding CG14440, Gpdh, or Synaptjanin-like and homologous proteins. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the sequences specific for the gene to detect transformants containing DNA or RNA encoding the corresponding protein. As used herein 'oligonucleotides' or 'oligomers' refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides, which can be used as a probe or amplifier.

A variety of protocols for detecting and measuring the expression of proteins, using either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on the protein is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; Serological Methods, a Laboratory Manual, APS Press, St Paul, Minn.) and Maddox, D. E. et al. (1983; J. Exp. Med. 158:1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding CG14440, Gpdh, 5 or Synaptjanin-like and homologous proteins include oligo-labeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide.

Alternatively, the sequences encoding the protein or any portions thereof may be cloned into a vector for the production of an mRNA probe. Such 10 vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, Mich.); Promega (Madison Wis.); and 15 U.S. Biochemical Corp., (Cleveland, Ohio).

Suitable reporter molecules or labels, which may be used, include 20 radiornuclides, enzymes, fluorescent, chemiluminescent or chromogenic agents as well as substrates, co-factors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding the protein may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a recombinant cell 25 may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode the protein may be designed to contain signal sequences, which direct secretion of the protein through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may be used to join sequences encoding the 30 protein to nucleotide sequence encoding a polypeptide domain, which will facilitate purification of soluble proteins. Such purification facilitating

domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAG extension/affinity purification system (Immunex Corp., Seattle, Wash.) The inclusion of cleavable linker sequences such as those specific for Factor XA or Enterokinase (Invitrogen, San Diego, Calif.) between the purification domain and the desired protein may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing the desired protein and a nucleic acid encoding 6 histidine residues preceding a thioredoxine or an Enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilised metal ion affinity chromatography as described in Porath, J. et al. (1992, Prot. Exp. Purif. 3: 263-281)) while the Enterokinase cleavage site provides a means for purifying the desired protein from the fusion protein. A discussion of vectors which are suitable for the production of fusion proteins is provided in Kroll, D. J. et al. (1993; DNA Cell Biol. 12:441-453). In addition to recombinant production, fragments of the proteins may be produced by direct peptide synthesis using solid-phase techniques (Merrifield J. (1963) J. Am. Chem. Soc. 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A peptide synthesizer (Perkin Elmer). Various fragments of the proteins may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

#### Diagnostics and Therapeutics

The data disclosed in this invention show that the nucleic acids and proteins of the invention are useful in diagnostic and therapeutic applications implicated, for example but not limited to, in metabolic disorders such as obesity as well as related disorders such as eating

disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancer, e.g. cancers of the reproductive organs, and sleep apnea. Hence, diagnostic and therapeutic uses for the CG14440, Gpdh, or Synaptjanin-like nucleic acids and proteins of the invention are, for example but not limited to, the following: (i) protein therapeutic, (ii) small molecule drug target, (iii) antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) diagnostic and/or prognostic marker, (v) gene therapy (gene delivery/gene ablation), (vi) research tools, and (vii) tissue regeneration in vitro and in vivo (regeneration for all these tissues and cell types composing these tissues and cell types derived from these tissues).

The nucleic acids and proteins of the invention are useful in diagnostic and therapeutic applications implicated in various applications as described below. For example, but not limited to, cDNAs encoding the CG14440, Gpdh, or Synaptjanin-like proteins of the invention and particularly their human homologues may be useful in gene therapy, and the CG14440, Gpdh, or Synaptjanin-like proteins of the invention and particularly their human homologues may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from, for example, but not limited to, in metabolic disorders as described above.

The novel nucleic acid encoding the CG14440, Gpdh, or Synaptjanin-like protein of the invention or homologous proteins or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acids or the proteins are to be assessed. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods.

For example, in one aspect, antibodies which are specific for CG14440, Gpdh, or Synaptojanin-like and homologous proteins may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express the protein. The antibodies may be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimerical, single chain, Fab fragments, and fragments produced by a Fab expression library. Neutralising antibodies, (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with the protein or any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminium hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol.

Among adjuvants used in human, BCG (Bacille Calmette-Guerin) and Corynebacterium parvum are especially preferable. It is preferred that the peptides, fragments or oligopeptides used to induce antibodies to the protein have an amino acid sequence consisting of at least five amino acids, and more preferably at least 10 amino acids. It is preferable that they are identical to a portion of the amino acid sequence of the natural protein, and they may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of CG14440, Gpdh, or Synaptojanin-like and homologous protein amino acids may be fused with those of another protein such as keyhole limpet hemocyanin in order to increase the immunogenicity.

Monoclonal antibodies to the proteins may be prepared using any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the

- 5 EBV-hybridoma technique (Köhler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R. J. et al. *Proc. Natl. Acad. Sci.* 80:2026-2030; Cole, S. P. et al. (1984) *Mol. Cell Biol.* 62:109-120).

- 10 In addition, techniques developed for the production of 'chimeric antibodies', the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison, S. L. et al. (1984) *Proc. Natl. Acad. Sci.* 81:6851-6855; Neuberger, M. S. et al. (1984) *Nature* 312:604-608;

- 15 Takeda, S. et al. (1985) *Nature* 314:452-454). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce single chain antibodies specific for CG14440, Gpdh, or Synaptosomal-like and homologous proteins. Antibodies with related specificity, but of distinct idiotypic  
20 composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton, D. R. (1991) *Proc. Natl. Acad. Sci.* 88:11120-3). Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as  
25 disclosed in the literature (Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci.* 86:3833-3837; Winter, G. et al. (1991) *Nature* 349:293-299).

Antibody fragments which contain specific binding sites for the proteins may also be generated. For example, such fragments include, but are not limited to, the F(ab')<sub>2</sub> fragments which can be produced by Pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of F(ab')<sub>2</sub> fragments.

Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse, W. D. et al. (1989) Science 254: 1275-1281).

- 5 Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding and immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation
- 10 between the protein and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering protein epitopes are preferred, but a competitive binding assay may also be employed (Maddox, *supra*).
- 15 In another embodiment of the invention, the polynucleotides encoding CG14440, Gpdh, or Synaptjanin-like and homologous proteins or any fragment thereof or antisense molecules, may be used for therapeutic purposes. In one aspect, antisense molecules may be used in situations in which it would be desirable to block the transcription of the mRNA. In
- 20 particular, cells may be transformed with sequences complementary to polynucleotides encoding CG14440, Gpdh, or Synaptjanin-like and homologous proteins. Thus, antisense molecules may be used to modulate protein activity or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligomers or larger
- 25 fragments, can be designed from various locations along the coding or control regions of sequences encoding the proteins. Expression vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses or from various bacterial plasmids may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods, which
- 30 are well known to those skilled in the art, can be used to construct recombinant vectors, which will express antisense molecules complementary to the polynucleotides of the genes encoding CG14440,

Gpdh, or Synaptojanin-like and homologous proteins. These techniques are described both in Sambrook et al. (supra) and in Ausubel et al. (supra). Genes encoding CG14440, Gpdh, or Synaptojanin-like and homologous proteins can be turned off by transforming a cell or tissue with expression vectors which express high levels of polynucleotide which encodes CG14440, Gpdh, or Synaptojanin-like and homologous proteins or fragments thereof. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing antisense molecules, e.g. DNA, RNA or PNA, to the control regions of the genes encoding CG14440, Gpdh, or Synaptojanin-like and homologous proteins, i.e., the promoters, enhancers, and introns. Oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it cause inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J. E. et al. (1994) In; Huber, B. E. and B. I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, N.Y.). The antisense molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

30

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves

sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples, which may be used, include engineered hammerhead motif ribozyme molecules that can be specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding CG14440, Gpdh, or Synaptjanin-like and homologous proteins. Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Antisense molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding CG14440, Gpdh, or Synaptjanin-like and homologous proteins. Such DNA sequences may be incorporated into a variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells or tissues. RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterate linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of non-traditional bases such as inosine, queosine, and

wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

- 5 Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection and by liposome injections may be achieved using  
10 methods, which are well known in the art. Any of the therapeutic methods described above may be applied to any suitable subject including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.
- 15 An additional embodiment of the invention relates to the administration of a pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of CG14440, Gpdh, or Synaptojanin-like and homologous nucleic acids or proteins, antibodies to  
20 CG14440, Gpdh, or Synaptojanin-like and homologous proteins, mimetics, agonists, antagonists or inhibitors of CG14440, Gpdh, or Synaptojanin-like and homologous proteins or nucleic acids. The compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile,  
25 biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone or in combination with other agents, drugs or hormones. The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to,  
30 oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations which, can be used pharmaceutically. Further 5 details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.). Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such 10 carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through 15 combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose or sodium carboxymethylcellulose; gums including Arabic and tragacanth; and proteins such as gelatine and collagen. If desired, disintegrating or solubilising agents may be added, 20 such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate. Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum Arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added 25 to the tablets or dragee coating for product identification or to characterize the quantity of active compound, i.e., dosage. Pharmaceutical preparations, which can be used orally, include push-fit capsules made of 30

- gelatine, as well as soft, sealed capsules made of gelatine and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers.
- 5 In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution or physiologically buffered saline. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil or synthetic fatty acid esters, such as ethyl oleate or triglycerides or liposomes. Optionally, the suspension may also contain suitable stabilizers or agents who increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

25 The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulphuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in

aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use. After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of proteins, such labeling would include amount, frequency, and method of administration.

10 Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art. For any compounds, the therapeutically effective doses can be estimated initially  
15 either in cell culture assays, e.g., of preadipocyte cell lines or in animal models, usually mice, rabbits, dogs or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. A therapeutically effective dose refers to that amount of active ingredient, for example CG14440,  
20 Gpdh, or Synaptjanin-like and homologous proteins or nucleic acids or fragments thereof, antibodies of CG1444O, Gpdh, or Synaptjanin-like and homologous proteins, which is sufficient for treating a specific condition. Therapeutic efficacy and toxicity may be determined by standard  
25 pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions, which exhibit large therapeutic indices, are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage  
30 for human use. The dosage contained in such compositions is preferably

within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration. The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors, which may be taken into account, include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week or once every two weeks depending on half-life and clearance rate of the particular formulation. Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

In another embodiment, antibodies which specifically bind to the proteins may be used for the diagnosis of conditions or diseases characterized by or associated with over- or underexpression of CG14440, Gpdh, or Synaptojanin-like and homologous proteins or in assays to monitor patients being treated with CG14440, Gpdh, or Synaptojanin-like and homologous proteins, agonists, antagonists or inhibitors. The antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays include methods which utilize the antibody and a label to detect the protein in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by joining them, either covalently or

non-covalently, with a reporter molecule. A wide variety of reporter molecules which are known in the art may be used several of which are described above.

- 5 A variety of protocols including ELISA, RIA, and FACS for measuring  
proteins are known in the art and provide a basis for diagnosing altered or  
abnormal levels of gene expression. Normal or standard values for gene  
expression are established by combining body fluids or cell extracts taken  
from normal mammalian subjects, preferably human, with antibodies to the  
10 protein under conditions suitable for complex formation. The amount of  
standard complex formation may be quantified by various methods, but  
preferably by photometry, means. Quantities of protein expressed in  
control and disease, samples from biopsied tissues are compared with the  
standard values. Deviation between standard and subject values  
15 establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides specific for CG14440, Gpdh, or Synaptosomal-like and homologous proteins may be used for diagnostic purposes. The polynucleotides, which may be used, include oligonucleotide sequences, antisense RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which gene expression may be correlated with disease. The diagnostic assay may be used to distinguish between absence, presence, and excess gene expression, and to monitor regulation of protein levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding CG14440, Gpdh, or Synaptjanin-like and homologous proteins or closely related molecules, may be used to identify nucleic acid sequences which encode the respective protein. The specificity of the probe, whether it is made from a highly specific region, e.g., unique

nucleotides in the 5' regulatory region or a less specific region, e.g., especially in the 3' coding region, and the stringency of the hybridization or amplification (maximal, high, intermediate or low) will determine whether the probe identifies only naturally occurring sequences, alleles or related sequences. Probes may also be used for the detection of related sequences, and should preferably contain at least 50% of the nucleotides from any of the CG14440, Gpdh, or Synaptjanin-like and homologous protein-encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and derived from the nucleotide sequence of the polynucleotide encoding CG14440 (GadFly Accession Number), the human hypothetical protein LOC55565, Gpdh (Glycerol 3 phosphate dehydrogenase, GadFly Accession Number CG9O42), the human soluble glycerol-3-phosphate dehydrogenase 1, CG7956 (GadFly Accession Number), or the human KIAA0966 protein or from a genomic sequence including promoter, enhancer elements, and introns of the naturally occurring gene. Means for producing specific hybridization probes for DNAs encoding CG14440, Gpdh, or Synaptjanin-like and homologous proteins include the cloning of nucleic acid sequences specific for CG14440, Gpdh, or Synaptjanin-like and homologous proteins into vectors for the production of mRNA probes. Such vectors are known in the art, commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, radionuclides such as 32P or 35S or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences specific for CG14440, Gpdh, or Synaptjanin-like and homologous nucleic acids may be used for the diagnosis of conditions or diseases, which are associated with the expression of the proteins. Examples of such conditions or diseases include, but are not limited to, pancreatic diseases and disorders, including diabetes. Polynucleotide

- sequences specific for CG1444O, Gpdh, or Synaptojanin-like and homologous proteins may also be used to monitor the progress of patients receiving treatment for pancreatic diseases and disorders, including diabetes. The polynucleotide sequences may be used in Southern or
- 5 Northern analysis, dot blot or other membrane-based technologies; in PCR technologies; or in dip stick, pin, ELISA or chip assays utilizing fluids or tissues from patient biopsies to detect altered gene expression. Such qualitative or quantitative methods are well known in the art.
- 10 In a particular aspect, the nucleotide sequences specific for CG1444O, Gpdh, or Synaptojanin-like and homologous nucleic acids may be useful in assays that detect activation or induction of various metabolic diseases such as obesity as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease,
- 15 hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancers of the reproductive organs, and sleep apnea. The nucleotide sequences may be labeled by standard methods, and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and
- 20 the signal is quantitated and compared with a standard value. If the amount of signal in the biopsied or extracted sample is significantly altered from that of a comparable have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding CG1444O, Gpdh, or Synaptojanin-like and homologous proteins in the sample indicates the presence of the associated disease. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials or in monitoring the
- 25 treatment of an individual patient.
- 30 In order to provide a basis for the diagnosis of a disease associated with expression of CG1444O, Gpdh, or Synaptojanin-like and homologous proteins, a normal or standard profile for expression is established. This

may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence or a fragment thereof, which is specific for CG1444O, Gpdh, or Synaptjanin-like and homologous nucleic acids, under conditions suitable for hybridization or 5 amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with those from an experiment where a known amount of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for 10 disease. Deviation between standard and subject values is used to establish the presence of disease. Once disease is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to evaluate whether the level of expression in the patient begins to approximate that, which is observed in the normal patient. The 15 results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to metabolic diseases such as obesity as well as related disorders such as eating disorder, cachexia, diabetes mellitus, 20 hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancers of the reproductive organs, and sleep apnea the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease or may provide a means for detecting the disease prior to 25 the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the pancreatic diseases and disorders. Additional diagnostic uses for oligonucleotides designed from the sequences encoding 30 CG1444O, Gpdh, or Synaptjanin-like and homologous proteins may involve the use of PCR. Such oligomers may be chemically synthesized, generated enzymatically or produced from a recombinant source. Oligomers

will preferably consist of two nucleotide sequences, one with sense orientation (5'.fwdarw.3') and another with antisense (3'.rarw.5'), employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantification of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of CG14440, Gpdh, or Synaptjanin-like include radiolabeling or biotinyling nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated (Melby, P. C. et al. (1993) J. Immunol. Methods, 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236). The speed of quantification of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantification.

In another embodiment of the invention, the nucleic acid sequences which are specific for CG14440, Gpdh, or Synaptjanin-like and homologous nucleic acids may also be used to generate hybridization probes, which are useful for mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. Such techniques include FISH, FACS or artificial chromosome constructions, such as yeast artificial chromosomes, bacterial artificial chromosomes, bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price, C. M. (1993) Blood Rev. 7: 127-134, and Trask, B. J. (1991) Trends Genet. 7:149-154. FISH (as described in Verma et al. (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York, N.Y.) may be correlated with other physical chromosome mapping techniques and genetic map data. Examples of genetic map data can be

found in the 1994 Genome Issue of Science (265:1981f). Correlation between the location of the gene encoding CG14440, Gpdh, or Synaptojanin-like on a physical chromosomal map and a specific disease or predisposition to a specific disease, may help to delimit the region of DNA associated with that genetic disease.

The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier or affected individuals. In situ hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11 q22-23 (Gatti, R. A., et al., (1988) Nature 336:577-580), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequences of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier or affected individuals.

In another embodiment of the invention, CG14440, Gpdh, or Synaptojanin-like and homologous proteins, their catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening libraries of compounds, e.g. peptides or low-molecular weight organic compounds, in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. The formation of binding

complexes, between CG14440, Gpdh, or Synaptojanin-like and homologous proteins and the agent tested, may be measured.

Another technique for drug screening, which may be used, provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, as applied to CG14440, Gpdh, or Synaptojanin-like and homologous proteins large numbers of different small test compounds, e.g. peptidic compounds or low-molecular weight organic molecules, are provided or synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with the proteins or fragments thereof, and washed. Bound proteins are then detected by methods well known in the art. Purified proteins can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support. In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding the protein specifically compete with a test compound for binding the protein. In this manner, the antibodies can be used to detect the presence of any peptide, which shares one or more antigenic determinants with the protein. In additional embodiments, the nucleotide sequences which are specific for CG14440, Gpdh, or Synaptojanin-like and homologous nucleic acids or proteins encoded thereby may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

The Figures show:

30

FIGURE 1 shows the increase of triglyceride content of PX10162.1 flies ('PX10162.1', column 2) caused by homozygous viable integration of the

P-vector upstream of the CG14440 gene (in comparison to controls without integration of this vector, 'PX-control', column 1).

5 FIGURE 2 shows the molecular organization of the mutated CG14440 (Gadfly Accession Number) gene locus.

FIGURE 3 shows the BLASTP search result for the CG14440 gene product (Query) with the best human homologous match (Sbjct).

10 FIGURE 4 shows the increase of triglyceride content of HD-EP(2)21956 ('HD-EP(2)21956', column 2) flies caused by homozygous viable integration of the P-vector into the second intron of CG9042 (in comparison to controls without integration of this vector, 'EP-control', column 1).

15 FIGURE 5 shows the molecular organization of the mutated Gpdh (Gadfly Accession Number CG9042) gene locus.

20 FIGURE 6 shows the BLASTP search result for the CG9042 gene product (Query) with the best human homologous match (Sbjct).

25 FIGURE 7 shows the increase of triglyceride content of HD-EP(3)31805 ('HD-EP31805', column 2) flies caused by homozygous viable integration of the P-vector 3 basepairs 5' of CG7956 (in comparison to controls without integration of this vector, 'EP-control', column 1).

FIGURE 8 shows the molecular organization of the mutated CG7956 (Gadfly Accession Number) gene locus.

30 FIGURE 9 shows the BLASTP search result for the CG7956 gene product (Query) with the best human homologous match (Sbjct).

The examples illustrate the invention:

Example 1: Measurement of triglyceride content

- 5      Mutant flies are obtained from a fly mutation stock collection. The flies are grown under standard conditions known to those skilled in the art. In the course of the experiment, additional feedings with bakers yeast (*Saccharomyces cerevisiae*) are provided for the EP-lines HD-EP(2)21956 and HD-EP(3)31805. The average increase of triglyceride content of
- 10     Drosophila containing the EP-vectors as homozygous viable integration was investigated in comparison to control flies (see FIGURES 1, 4 and 7). For determination of triglyceride, flies (in case of PX10162.1, ten flies in two independent assays, respectively) were incubated for 5 min at 90°C (in case of PX10162.1 at 70°C) in an aqueous buffer using a waterbath, followed by hot extraction. After another 5 min incubation at 90°C (in case of PX10162.1 at 70°C) and mild centrifugation, the triglyceride content of the flies extract was determined using Sigma Triglyceride (INT 336-10 or -20) assay by measuring changes in the optical density according to the manufacturer's protocol. In case of the EP-lines
- 15     HD-EP(2)21956 and HD-EP(3)31805, as a reference the protein content of the same extract was measured using BIO-RAD DC Protein Assay according to the manufacturer's protocol. These assays were repeated three times.
- 20     The average triglyceride level of about 50 lines of the PX collection (referred to as 'PX-control') is shown as 100% (relative amount of triglyceride per fly) in the first column in FIGURE 1. The average triglyceride level of all flies of the EP collection (referred to as 'EP-control') is shown as 100% in the first columns in FIGURE 4 and 7. Standard deviations of the measurements are shown as thin bars.
- 25
- 30

- PX10162.1 homozygous flies show constantly a higher triglyceride content than the controls (38%; column 2 in FIGURE 1, 'PX10162.1'). Therefore, the loss of gene activity in the locus 6C7 on chromosome X where the EP-vector of PX10162.1 flies is homozygous viable integrated, is responsible for changes in the metabolism of the energy storage triglycerides, therefore representing a model for obese flies. The findings suggest the presence of similar functions of the homologous proteins in humans.
- HD-EP(2)21956 homozygous flies show constantly a higher triglyceride content than the controls (67% ; column 2 in FIGURE 4, 'HD-EP(2)21956'). Therefore, the loss of gene activity in the locus 26A8 on chromosome 2L where the EP-vector of HD-EP(2)21956 flies is homozygous viable integrated, is responsible for changes in the metabolism of the energy storage triglycerides.
- HD-EP(3)31805 homozygous flies show constantly a higher triglyceride content than the controls (45% ; column 2 in FIGURE 7, 'HD-EP31805'). Therefore, the loss of gene activity in the locus 93E4 on chromosome 3R where the EP-vector of HD-EP(3)31805 flies is homozygous viable integrated, is responsible for changes in the metabolism of the energy storage triglycerides.

#### Example 2: Identification of the genes

Genomic DNA sequences were isolated that are localized to the EP vector (herein PX10162.1) integration. Using those isolated genomic sequences public databases like Berkeley Drosophila Genome Project (GadFly) were screened thereby confirming the homozygous viable integration site of the PX10162.1 vector upstream of the 5'-end of a Drosophila gene, identified as CG14440 (GadFly Accession Number). FIGURE 2 shows the molecular organization of this gene locus. The chromosomal localization site of the

integration of the vector of PX10162.1 is at gene locus X, 6C7. In FIGURE 2, genomic DNA sequence is represented by the assembly as a dotted grey line in the middle that includes the integration sites of vector for line PX10162.1. Numbers represent the coordinates of the genomic DNA (starting at position 6494082 on chromosome X, ending at position 6519082 on chromosome X). The insertion site of the P-element in Drosophila PX10162.1 line is shown as '+' on the dotted line and as vertical line. Dark grey boxes on the lower "cDNA"-line, linked by light grey boxes, represent the predicted genes (as predicted by the Berkeley Drosophila Genome Project, GadFly and by Magpie). Predicted exons are shown as dark grey boxes, predicted introns are shown as light grey boxes. The gene CG14440 is labeled. Transcribed DNA sequences (ESTs) are shown as grey bars in the lower "EST" line. Therefore, expression of the cDNA encoding CG14440 (GadFly Accession Number) could be affected by homozygous integration of vectors of line PX10162.1, leading to an increase of the energy storage triglycerides.

Genomic DNA sequences were isolated that are localized to the EP vector (herein HD-EP(2)21956) integration. Using those isolated genomic sequences public databases like Berkeley Drosophila Genome Project (GadFly) were screened thereby confirming the homozygous viable integration site of the HD-EP(2)21956 vector into the second intron of a Drosophila gene in sense orientation, identified as Gpdh (GadFly Accession Number CG9042). FIGURE 5 shows the molecular organization of this gene locus. The chromosomal localization site of the integration of the vector of HD-EP(2)21956 is at gene locus 2L, 26A8. In FIGURE 5, genomic DNA sequence is represented by the assembly as a dotted grey line in the middle that includes the integration sites of vector for line HD-EP(2)21956. Numbers represent the coordinates of the genomic DNA (starting at position 5861000 on chromosome 2L, ending at position 5867250 on chromosome 2L). The insertion site of the P-element in Drosophila HD-EP(2)21956 line is shown as triangle in the upper "P Elements" line and

is labeled. Dark grey boxes on the upper "cDNA"-line, linked by light grey boxes, represent the predicted genes (as predicted by the Berkeley Drosophila Genome Project, GadFly and by Magpie). Predicted exons are shown as dark grey boxes, predicted introns are shown as light grey boxes. The gene CG9042 is labeled. Transcribed DNA sequences (ESTs) are shown as grey bars in the upper "EST" line. Therefore, expression of the cDNA encoding Gpdh (Accession Number CG9042) could be affected by homozygous integration of vectors of line HD-EP(2)21956, leading to an increase of the energy storage triglycerides.

10

Genomic DNA sequences were isolated that are localized to the EP vector (herein HD-EP(3)31805) integration. Using those isolated genomic sequences public databases like Berkeley Drosophila Genome Project (GadFly) were screened thereby confirming the homozygous viable integration site of the HD-EP(3)31805 vector 3 base pairs 5' of a Drosophila gene in antisense orientation, identified as CG7956 (GadFly Accession Number). FIGURE 8 shows the molecular organization of this gene locus. The chromosomal localization site of the integration of the vector of HD-EP(3)31805 is at gene locus 3R, 93E4. In FIGURE 8, genomic DNA sequence is represented by the assembly as a dotted grey line in the middle that includes the integration sites of vector for line HD-EP(3)31805. Numbers represent the coordinates of the genomic DNA (starting at position 17260000 on chromosome 3R, ending at position 17270000 on chromosome 3R). The insertion site of the P-element in Drosophila HD-EP(3)31805 line is shown as triangle in the lower "P Elements" line and is labeled. Dark grey boxes on the upper "cDNA"-line, linked by light grey boxes, represent the predicted genes (as predicted by the Berkeley Drosophila Genome Project, GadFly and by Magpie). Predicted exons are shown as dark grey boxes, predicted introns are shown as light grey boxes. The gene CG7956 is labeled. Transcribed DNA sequences (ESTs) are shown as grey bars in the upper "EST" line. Therefore, expression of the cDNA encoding CG7956 (GadFly Accession Number) could be affected

15

20

25

30

by homozygous integration of vectors of line HD-EP(3)31805, leading to an increase of the energy storage triglycerides.

5 Example 3: Identification of human CG14440, Gpdh, or Synaptjanin-like homologous proteins


CG14440, Gpdh, or Synaptjanin-like homologous proteins and nucleic acid molecules coding therefore are obtainable from insect or vertebrate species, e.g. mammals or birds. Particularly preferred are nucleic acids comprising CG14440 (GadFly Accession Number), the human hypothetical protein LOC55565, Gpdh (Glycerol 3 phosphate dehydrogenase, GadFly Accession Number CG9042), the human soluble glycerol-3-phosphate dehydrogenase 1, CG7956 (GadFly Accession Number), and the human KIAA0966 protein.

15 As shown in FIGURE 3, gene product of GadFly Accession Number CG14440 is 57% homologous to human hypothetical protein LOC55565 (GenBank Accession Number NP\_060000.1 for the protein, NM\_017530 for the cDNA). CG14440 also shows 58% homology on protein level to mouse protein similar to hypothetical protein LOC55565 (GenBank Accession Number AAH23180.1).

20 As shown in FIGURE 6, gene product of GadFly Accession Number CG9042 is 72% homologous to human soluble glycerol-3-phosphate dehydrogenase 1 (GenBank Accession Number XP\_006755.1 for the protein, XM\_006755 for the cDNA). CG9042 also shows 72% homology on protein level to mouse cytoplasmic adult glycerophosphate dehydrogenase 1 (GenBank Accession Number NP\_034401.1).

30 As shown in FIGURE 9, gene product of GadFly Accession Number CG7956 is 52% homologous to human KIAA0966 protein (GenBank Accession Number NP\_055752.1 for the protein, NM\_014937 for the

cDNA). CG7956 also shows 57% homology on protein level to mouse protein ENSMUSP00000045910 (ENSEMBL Accession Number).



EPO - Munich  
80  
16. Mai 2002

## Claims

1. A pharmaceutical composition comprising a nucleic acid molecule of the CG14440, Gpdh, or Synaptjanin-like gene family or a polypeptide encoded thereby or a fragment or a variant of said nucleic acid molecule or said polypeptide or an antibody, an aptamer or another receptor recognizing a nucleic acid molecule of the CG14440, Gpdh, or Synaptjanin-like gene family or a polypeptide encoded thereby together with pharmaceutically acceptable carriers, diluents and/or adjuvants.
2. The composition of claim 1, wherein the nucleic acid molecule is a vertebrate or insect CG14440, Gpdh, or Synaptjanin-like nucleic acid, particularly encoding the human hypothetical protein LOC55565, the human soluble glycerol-3-phosphate dehydrogenase 1, or the human KIAA0966 protein, and/or a nucleic molecule which is complementary thereto or a fragment thereof or a variant thereof.
3. The composition of claim 1 or 2, wherein said nucleic acid molecule
  - (a) hybridizes at 50°C in a solution containing 1 x SSC and 0.1 % SDS to a nucleic acid molecule as defined in claim 2 and/or a nucleic acid molecule which is complementary thereto;
  - (b) it is degenerate with respect to the nucleic acid molecule of (a),
  - (c) encodes a polypeptide which is at least 85%, preferably at least 90%, more preferably at least 95%, more preferably at least 98% and up to 99,6% identical to the human hypothetical protein LOC55565, the human soluble glycerol-3-phosphate dehydrogenase 1, or the human KIAA0966 protein, as defined in claim 2;

- (d) differs from the nucleic acid molecule of (a) to (c) by mutation and wherein said mutation causes an alteration, deletion, duplication or premature stop in the encoded polypeptide.
- 5      4. The composition of any one of claims 1-3, wherein the nucleic acid molecule is a DNA molecule, particularly a cDNA or a genomic DNA.
- 10     5. The composition of any one of claims 1-4, wherein said nucleic acid encodes a polypeptide contributing to regulating the energy homeostasis and/or the metabolism of triglycerides.
- 15     6. The composition of any one of claims 1-5, wherein said nucleic acid molecule is a recombinant nucleic acid molecule.
- 20     7. The composition of any one of claims 1-6, wherein the nucleic acid molecule is a vector, particularly an expression vector.
- 25     8. The composition of any one of claims 1-5, wherein the polypeptide is a recombinant polypeptide.
- 30     9. The composition of claim 8, wherein said recombinant polypeptide is a fusion polypeptide.
10. The composition of any one of claims 1-7, wherein said nucleic acid molecule is selected from hybridization probes, primers and anti-sense oligonucleotides.
11. The composition of any one of claims 1-10 which is a diagnostic composition.
12. The composition of any one of claims 1-10 which is a therapeutic composition.

- 5           13. The composition of any one of claims 1-12 for the manufacture of an agent for detecting and/or verifying, for the treatment, alleviation and/or prevention of disorders, including metabolic diseases such as obesity and other body-weight regulation disorders as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancer, e.g. cancers of the reproductive organs, and sleep apnea and others, in cells, cell masses, organs and/or subjects.
- 10           14. Use of a nucleic acid molecule of the CG14440, Gpdh, or Synaptjanin-like gene family or a polypeptide encoded thereby or a fragment or a variant of said nucleic acid molecule or said polypeptide or an antibody, an aptamer or another receptor recognizing a nucleic acid molecule of the CG14440, Gpdh, or Synaptjanin-like gene family or a polypeptide encoded thereby for controlling the function of a gene and/or a gene product which is influenced and/or modified by a CG14440, Gpdh, or Synaptjanin-like homologous polypeptide.
- 15           15. Use of the nucleic acid molecule of the CG14440, Gpdh, or Synaptjanin-like gene family or a polypeptide encoded thereby or a fragment or a variant of said nucleic acid molecule or said polypeptide or an antibody, an aptamer or another receptor recognizing a nucleic acid molecule of the CG14440, Gpdh, or Synaptjanin-like gene family or a polypeptide encoded thereby for identifying substances capable of interacting with a CG14440, Gpdh, or Synaptjanin-like homologous polypeptide.
- 20           16. A non-human transgenic animal exhibiting a modified expression of a CG14440, Gpdh, or Synaptjanin-like homologous polypeptide.
- 25

17. The animal of claim 16, wherein the expression of the CG14440, Gpdh, or Synaptojanin-like homologous polypeptide is increased and/or reduced.
- 5 18. A recombinant host cell exhibiting a modified expression of a CG14440, Gpdh, or Synaptojanin-like homologous polypeptide.
19. The cell of claim 18 which is a human cell.
- 10 20. A method of identifying a (poly)peptide involved in the regulation of energy homeostasis and/or metabolism of triglycerides in a mammal comprising the steps of
  - (a) contacting a collection of (poly)peptides with a CG14440, Gpdh, or Synaptojanin-like homologous polypeptide or a fragment thereof under conditions that allow binding of said (poly)peptides;
  - (b) removing (poly)peptides which do not bind and
  - (c) identifying (poly)peptides that bind to said CG14440, Gpdh, or Synaptojanin-like homologous polypeptide. ....
- 20 21. A method of screening for an agent which modulates the interaction of a CG14440, Gpdh, or Synaptojanin-like homologous polypeptide with a binding target/agent, comprising the steps of
  - (a) incubating a mixture comprising
    - (aa) a CG14440, Gpdh, or Synaptojanin-like homologous polypeptide or a fragment thereof;
    - (ab) a binding target/agent of said CG14440, Gpdh, or Synaptojanin-like homologous polypeptide or fragment thereof; and
    - (ac) a candidate agent

under conditions whereby said CG14440, Gpdh, or Synaptjanin-like polypeptide or fragment thereof specifically binds to said binding target/agent at a reference affinity;

- 5 (b) detecting the binding affinity of said CG14440, Gpdh, or Synaptjanin-like polypeptide or fragment thereof to said binding target to determine an (candidate) agent-biased affinity; and
- (c) determining a difference between (candidate) agent-biased affinity and the reference affinity.

10 22. A method of producing a composition comprising the (poly)peptide identified by the method of claim 20 or the agent identified by the method of claim 21 with a pharmaceutically acceptable carrier, diluent and/or adjuvant.

15 23. The method of claim 22 wherein said composition is a pharmaceutical composition for preventing, alleviating or treating of diseases and disorders, including metabolic diseases such as obesity and other body-weight regulation disorders as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancer, e.g. cancers of the reproductive organs, and sleep apnea and other diseases and disorders.

25 24. Use of a (poly)peptide as identified by the method of claim 20 or of an agent as identified by the method of claim 21 for the preparation of a pharmaceutical composition for the treatment, alleviation and/or prevention of diseases and disorders, including metabolic diseases such as obesity and other body-weight regulation disorders as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease,

hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancer, e.g. cancers of the reproductive organs, and sleep apnea and other diseases and disorders.

- 5      25. Use of a nucleic acid molecule of the CG14440, Gpdh, or Synaptjanin-like family or of a fragment thereof for the preparation of a non-human animal which over- or under-expresses the CG14440, Gpdh, or Synaptjanin-like gene product.
- 10     26. Kit comprising at least one of
  - (a) a CG14440, Gpdh, or Synaptjanin-like nucleic acid molecule or a fragment thereof;
  - (b) a vector comprising the nucleic acid of (a);
  - (c) a host cell comprising the nucleic acid of (a) or the vector of (b);
  - (d) a polypeptide encoded by the nucleic acid of (a);
  - (e) a fusion polypeptide encoded by the nucleic acid of (a);
  - (f) an antibody, an aptamer or another receptor against the nucleic acid of (a) or the polypeptide of (d) or (e) and
  - 15     (g) an anti-sense oligonucleotide of the nucleic acid of (a).
- 20

EPO - Munich  
80


Abstract

16. Mai 2002

The present invention discloses CG14440, Gpdh, or Synaptjanin-like homologous proteins regulating the energy homeostasis and the metabolism of triglycerides, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders, for example, but not limited to, metabolic diseases such as obesity as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancers of the reproductive organs, and sleep apnea.

15


cl 16.05.2002




16. Mai 2002

EPO - Munich  
80  
16. Mai 2002

**FIGURE 1. Triglyceride content of a Drosophila CG14440 (GadFly Accession Number) mutant**



**FIGURE 2. Molecular organization of the CG14440 gene (GadFly Accession Number)**



16. Mai 201

**FIGURE 3. BLASTP results for CG14440 (GadFly Accession Number)**

**Homology to human protein NP\_060000.1 (GenBank Accession Number)**


ref|NP\_060000.1| (NM\_017530) hypothetical protein LOC55565 [Homo sapiens]  
Length = 370

Score = 77.4 bits (189), Expect = 2e-13  
Identities = 41/106 (38%), Positives = 62/106 (57%)


Query: 195 QGQSSRAQKAARRRSNESIEARERRLERNAARMRDKRAKESEA EYRVRLAKNAEANRVRR 254  
+ Q+ +K A RR NE +E R +RLER + +R E+ E VR ++ EA R++R  
Sbjct: 207 EAQTPSVRKWALRRQNEPLEVRLQRLERERTAKKSRRDNETPEEREVRRMRDREAKRLQR 266

Query: 255 QNETEVORTLRLMKNAARQRLRASETVEERKKRLAKAAERMRIAR 300  
ET+ QR RL ++ RL+RA+ET E+R+ RL + E R+ R  
Sbjct: 267 MQETDEQRARRLQRDREAMRLKRA NETPEKQARLIREREAKRLKR 312

**FIGURE 4. Triglyceride content of a *Drosophila Gpdh* (GadFly Accession Number CG9042) mutant**



**FIGURE 5. Molecular organisation of the *Gpdh* gene (GadFly Accession Number CG9042)**



Legend: █ GadFly, DGC, cDNA █ Magpie, clot █ EST

**FIGURE 6. BLASTP results for CG9042 (GadFly Accession Number)****Homology to human protein XP\_006755.1 (GenBank Accession Number)**

gi|11440382|ref|XP\_006755.1| (XM\_006755) glycerol-3-phosphate dehydrogenase 1  
 (soluble) [Homo sapiens] Length = 349

Score = 423 bits (1087), Expect = e-118  
 Identities = 217/351 (61%), Positives = 256/351 (72%), Gaps = 3/351 (0%)

Query: 1 MADKVNVCIVGSGNWSXXXXXXXXXXXXXXLPEFEERVTMFVYEEELIDGKKLTEIINETHE 60  
 MA K VCIVGSGNWS L +F+ RVTM+V+EE I GKKLTEIIN HE

Sbjct: 1 MASK-KVCIVGSGNWSAIAKIVGGNAAQLAQFDPRVTMWVFEEDIGGKKLTEIINTQHE. 59.

Query: 61 NVKYLGHKLPPNVVAVPDLVAAKNADILIFVVPHQFI PNFKCKQLLGKIKPNAAISLI 120  
 NVKYL GHKLPPNVVAVPD+V+AA++ADILIFVVPHQFI C QL G +K NA ISLI

Sbjct: 60 NVKYLPGHKLPPNVVAVPDVVQAAEDADILIFVVPHQFIGKICDQLKGHLKANATGISLI 119

Query: 121 KGFDKAEGGGIDLTSHITRHLKIPCAVLMGANLANEVAEGNFCETTIGCTDKKYGKVL 180  
 KG D+ G+ LIS +I L IP +VLMGAN+A+EVA+ FCETTIGC D G++L+

Sbjct: 120 KGVDEGP-NGLKLISEVIGERLGIPMSVLMGANIASEVADEKFCETTIGCKDPAQGQLLK 178

Query: 181 DLFQANHFRXXXXXXXXXXXXCGALKNIVACGAGFVDGLKLDNTKAAVIRLGLMEMIRF 240  
 +L Q +FR CGALKN+VA GAGF DGL GDNTKAAVIRLGLMEMI F

Sbjct: 179 ELMQTPNFRITVVQEVDTVEICGALKNVVAVGAGFCDGGLFGDNTKAAVIRLGLMEMIAF 238


Query: 241 VDVFYPGSKLS-TFFESCGVADLITTCYGGRRNRVSEAFVTSGKTIEELEKEMLNGQKLQ 299  
 +F G S TF ESCGVADLITTCYGGRRNR+V+EAF +GK+IE+LEKE+LNGQKLQ

Sbjct: 239 AKLFCSGPVSSATFLESCGVADLITTCYGGRRNRVAEAFARTGKSIEQLEKELLNGQKLQ 298


Query: 300 GPPTAEEVNYMLKNKGLEDKFPLFTAIIHKICTNQLKPNDLIDCIRNHPEHM 350  
 GP TA E+ +L++KGL DKFPLF A++K+C + I C++NHPEHM

Sbjct: 299 GPETARELYSILQHKGLVDKFPLFMAVYKVCYEGQPVGIFIHCLQNHPPEHM 349

**FIGURE 7. Triglyceride content of a Drosophila CG7956 (GadFly Accession Number) mutant**



**FIGURE 8. Molecular organization of the CG7956 gene (GadFly Accession Number)**



**FIGURE 9. BLASTP results for CG7956 (GadFly Accession Number)****Homology to human protein NP\_055752.1 (GenBank Accession Number)**

ref|NP\_055752.1| (NM\_014937) KIAA0966 protein [Homo sapiens]  
Length = 1132

Score = 573 bits (1477), Expect = e-162  
 Identities = 354/972 (36%), Positives = 514/972 (52%), Gaps = 114/972 (11%)

**Query:** 1 MEVFQTD SHYIFV KRDKS LWW HRR TSEFS IKA GWDL SSV DDI E CIGV THGIV GV ISLP NV 60  
**Sbjct:** 1 ME LFQAKD HYI L QQGER ALWC SRRD GGL QLR P AT D LLA WNP IC GL VEGV IGK IQL HSD 60 .

**Query:** 61 YEPHL VVV KEAS AVGV LVYP PHLV YKIK SIC IL S ADD -- PDT DLP NCT KHT KSN QST PTH 117  
**Sbjct:** 61 LPW WL LIL RQK ALVG KLP GDHEV CKV TKIA VL S L SEME P Q DLE ELCK KH----- 110

**Query:** 118 SV STS NM NN AS VPSS GGG SKS T KLF EG MNK T WG AVKS AG NT -- IK NT T QQA AN LAT KQ 174  
**Sbjct:** 111 ----- HFG INK PEKI IIPSP IDSK FLL KTF THIK SNV SAPN 145

**Query:** 175 VK SSVG IRE PRH IERR RITE ELHK I FDE TD SYF SF DCD IT NN LQR HEAK SEES Q --- SQP 231  
**Sbjct:** 146 KKK VKE KEK EKL RRL L ELL KM FMD S ESY SL TYDL T NSV QR QST GER DGR PLW QKV 205

**Query:** 232 DER FWN KHM IRDL I NLND KT -- WI LPI I QGF M QVN CVIG ----- 270  
**Sbjct:** 206 DDR FWN KHY MI QDL TE IGT PDV DF WI I PMI QGF VQIE ELV VNV TESS DDE KSS PET PP QE 265

**Query:** 271 NEC ----- FT LAL VSR SRH RAG TRY KRR GV D EKG NC A NY VET E Q ILS FRH HQ LSFT Q 323  
**Sbjct:** 266 STC VDD IH P RFL VAL IS RR SRH RAG MRY KRR GV DK NG NV A NY VET E Q LIH VH NH TL SFV Q 325

**Query:** 324 VR GSVP IY WS QPG YK RPP RL DRG VA ET QQAF E L HFT K E LET Y GRV CIV NL VE Q SG KEK 383  
**Sbjct:** 326 TRGS VPV FWS QVG YR YN P RPL DR SE KET VAY FCAH FEE Q LNI YKK QV I I NL VD QAG REK 385

**Query:** 384 TIG DAY ADHV I KLN ND RL I YV TFD FD HDY CRGM RF EN VS AL I DA VG P EA G AM GF H WRD Q RG 443  
**Sbjct:** 386 II GDAY LK QV LL FN NSH LT YVS FDF HEH CRGM K FEN V QTL TDAI YD I I LD MK WC W V DE AG 445

**Query:** 444. M ICN QKS VFR VN CM DC LDR TN VV QTA I GKA V LE SQL V KL GL SP PY TPI P EQL KSP FM VL W 503  
**Sbjct:** 446 VICK QEG I F R VNC MD C LDR TN VV QAA I ARV VM E Q QL KK LG V MP PE Q P L P V K CN RI Y QIM W 505

**Query:** 504 AN NG DI I S RQ YAG T N AL KGD Y TRT G ERK I S GM K DG M NS A N RY YL A RF K D S Y R Q A T ID LM 563  
**Sbjct:** 506 AN NG D S I S RQ YAG TA A L KGD FTR T G ERK L A G V M K D G V N S A N RY YL N R F K D A Y R Q A V ID LM 565

**Query:** 564 LGN QVS SES L S AL GG QAG PD -- END GTEN AE Q A K L L V ED C R R L L G T A Q Y P V G A W G L ID 620  
**Sbjct:** 566 QG I P V T E D L Y SIFT K E K E H E A L K E N Q R S H Q E L I S Q L L Q S Y M K L L P D E K F H G G W A L ID 625

**Query:** 621 ADP SSG D I N E T E V D T I L L L T D D C Y I V A E Y D S H L D K I V R F E K V Q L T Q V R L I E L G M H Q Q T K I 680  
**Sbjct:** 626 C D P S L I D A T H R D V D V L L L S N S A Y Y V A Y Y D D E V D K V N Q Y Q R L S L E N L E K I E I G -- P E P T L 683

**Query:** 681 F Q G S A P A H L C L R L N Y S V D E Q E G Y F H M F R S A N L R F F N N M A Y V I K T Q E E V A E S M T S I V E M F R 740  
**Sbjct:** 684 F -- G K P K F S C M R L H Y R Y K E A S G Y F H T L R ----- A V M R N P E E D G K D T L Q C I A E M L Q 731

Query: 741 IALDNAGNTEVRYITGGVLQRRKSKLPTLDV-----PRGMPRNLSESQQLVQLSSKA 791  
I G+ I L+R+ SK P D+ +N S+ L+ K  
Sbjct: 732 ITKQAMGSD--LPIIEKKLERKSSK-PHEDIIGIRSQNQGSLAQGKNFLMSKFSSLNQKV 788

Query: 792 LSNMA----GQFSKLGQTFFKPQAHPSSLAATMNPQVMRQRDSEIESGQEAEKAVFTLGR 847  
+ G KLG F KP+ + L + + + DS +E+ + V +  
Sbjct: 789 KQTGSNVNIGNLRKLG-NFTKPEMKVNFLKPNLKVNWLKS-DSSLETMENT--GVMDKVQ 844

Query: 848 KHRNSNSASSTDDEHDNSLYEPEVDSVDEIAMDKNYNE-NAFLPSVGIVMG---NQK 902  
+ + +S D+ D L + D D ++A + + LPS GI+ +  
Sbjct: 845 AESDGDMSSDNDSYHSDEFLTNSKSDEDRQLANSLESVGPIDYVLPSCGIIASAPRLGSR 904

Query: 903 EDSPSSSDEIRH 914  
S SS+D H  
Sbjct: 905 SQSLSSSTDSSVH 916

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**